No evidence of rapid reversibility of tenofovir alafenamide and/or integrase strand transfer inhibitor-associated weight gain

OBJECTIVE: We aimed to determine the reversibility of at least 7% weight gain within 12 months following tenofovir alafenamide (TAF) and/or integrase strand transfer inhibitor (INSTI) discontinuation in people with HIV (PWH) from the Dutch ATHENA cohort. DESIGN AND METHODS: PWH with at least 7% weig...

Descripción completa

Detalles Bibliográficos
Autores principales: Verburgh, Myrthe L., Wit, Ferdinand W.N.M., Boyd, Anders, Reiss, Peter, Van der Valk, Marc
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Clinical Science: Concise Communications
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10481918/
https://www.ncbi.nlm.nih.gov/pubmed/37433218
http://dx.doi.org/10.1097/QAD.0000000000003654

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10481918/
https://www.ncbi.nlm.nih.gov/pubmed/37433218
http://dx.doi.org/10.1097/QAD.0000000000003654

Ejemplares similares